MCAS Diagnostic Criteria âConsensus-2" with Dr. Lawrence Afrin as part of the Mast Cell Matters series
In this episode of 'Mast Cell Matters,' Dr. Lawrence Afrin discusses the new 'Consensus-2' diagnostic criteria for Mast Cell Activation Syndrome (MCAS) with Dr. Tania Dempsey. Dr. Afrin outlines the shortcomings of the first consensus statement, which heavily relied on elevated tryptase levels as a sole indicator for diagnosing MCAS. He argues for a more inclusive approach that considers a broader array of symptoms and biological markers, enabling more patients to be diagnosed even when tryptase levels are not elevated. This new consensus allows for a more nuanced diagnosis, acknowledging the complex and varied ways MCAS can present itself in patients. The conversation also highlights the variability in symptoms and underlying genetic mutations of the condition, making it challenging to diagnose and manage. They emphasize the importance of differing diagnostic approaches to account for the heterogeneity of MCAS and highlight the need for greater education and awareness among healthcare professionals about the syndrome.
